AGENUS INC (AGEN): M&A transaction — Agenus closes $75M sale of royalty and milestone rights to Ligand

AGENUS INC

Received $75M on May 30, 2024, for sale of milestone and royalty rights to Ligand Pharmaceuticals.
Sold 31.875% of development/regulatory/commercial milestone payments under five license agreements with BMS, Incyte, Merck, UroGen, Gilead.
Sold 18.75% of royalties from those agreements and 2.625% synthetic royalty on botensilimab/balstilimab net sales.
Transaction closed May 29, 2024; proceeds net of certain expenses.

item 2.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

AGENUS INC completed a disposition involving Ligand Pharmaceuticals Incorporated for $75 million (closed 2024-05-29).

Action: disposition
Counterparty: Ligand Pharmaceuticals Incorporated
Consideration: $75 million
Closing: 2024-05-29

Exact text from the filing

On May 29, 2024, the transactions contemplated by the Purchase Agreement closed. Pursuant to the Purchase Agreement, on May 30, 2024, Agenus received consideration of $75 million, less certain reimbursable expenses upon the completion of the sale to Ligand of the following assets: (i) 31.875% of the development, regulatory and commercial milestone

View on SEC.gov

68 m&a transactions filed in the last 30 days. Browse all m&a transactions →

AGENUS INC filing history →

Source: SEC EDGAR

accession 0000950170-24-066545

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.